Navigation Links
Faruqi & Faruqi, LLP Notifies Investors of June 4, 2012 Lead Plaintiff Deadline for the Class Action Filed Against Chelsea Therapeutics International
Date:5/29/2012

NEW YORK, May 29, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Chelsea Therapeutics International, Ltd. ("Chelsea" or the "Company") (Nasdaq: CHTP).   

(Logo:  http://photos.prnewswire.com/prnh/20120119/MM38856LOGO)

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that:  (1) Chelsea's Northera (droxidopa) product, an orally-active synthetic precursor of norepinephrine being developed for the treatment of symptomatic neurogenic orthostatic hypotension, would not receive approval from the U.S. Food and Drug Administration; and (2) the Company's numerous statements regarding the safety and efficacy of the product, as well as reportedly positive results from Northera's clinical trials, were materially false and misleading.

On February 13, 2012, Chelsea disclosed that the Food and Drug Administration ("FDA") had raised questions regarding the efficacy, size and duration of the Company's clinical trials for the drug Northera.  Furthermore, the FDA indicated that three deaths were potentially related to the drug's trials.  In the aftermath of these disclosures, Chelsea's stock price declined by more than 37 %. Then on March 28, 2012, the Company announced that its New Drug Application for Northera was rejected by the FDA. Upon this news, Chelsea shares fell more than 28%, to close at $2.62 per share on March 29, 2012.

Request more information now by clicking here:  www.faruqilaw.com/CHTP

Take Action

If you purchased Chelsea securities between November 3, 2008 and March 28, 2012 and would like to discuss your legal rights, visit www.faruqilaw.com/CHTP.  You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Chelsea's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential matter.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Francis McConville, Esq.
fmcconville@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

 


'/>"/>
SOURCE Faruqi & Faruqi, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Faruqi & Faruqi, LLP Announces Investigation of ZELTIQ Aesthetics, Inc.
4. Faruqi & Faruqi, LLP Announces Investigation of BioSante Pharmaceuticals, Inc.
5. Faruqi & Faruqi, LLP Announces Investigation of GenVec, Inc.
6. Masimo to Present at William Blair & Company 32nd Annual Growth Stock Conference
7. Acacia Pharma Announces Excellent Phase II Results for APD421 in Post-Operative Nausea & Vomiting (PONV)
8. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
9. Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market
10. Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
11. Medical Device Developers - Network at MD&M East Next Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for ... Vincent J. Angotti has been appointed ... company,s board of directors, effective Monday, March 6, ... experience leading executive and commercial teams at public ...
(Date:2/16/2017)... , Feb. 16, 2017  Prescription pain medications ... department visit are necessary for long-term opioid use to ... Feb. 16 th edition of The New ... "Emergency physicians see more patients in acute pain than ... Parker , MD, FACEP, president of the American College ...
(Date:2/16/2017)... Research and Markets has announced the addition of the ... Function, Application, Cancer Type, Technology - Forecast to 2025" report ... ... grow at a CAGR of around 28.6% over the next decade ... Some of the prominent trends that the market is witnessing include ...
Breaking Medicine Technology:
(Date:2/18/2017)... ... February 17, 2017 , ... Focused ... innovation in the industry, according to the recent NEJM Catalyst Insights Report on ... of the NEJM Catalyst Insights Council, a qualified group of U.S. executives, clinical ...
(Date:2/18/2017)... ... 2017 , ... A new directory from the Senior Veterans ... connect elderly veterans of America's armed forces to a range of senior care ... on this year's increase in the Veterans Pension with Aid & Attendance for ...
(Date:2/17/2017)... ... 2017 , ... For the first time, International Scholarship and ... floor for the 2017 HIMSS Conference & Exhibition at the Orange ... than 40,000 healthcare industry professionals are expected at the conference, where they will ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today ... Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will ... used electronic patient signatures solution in healthcare . , Since it first ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer diagnostics workflow solution provider ... 20 – 22 in San Francisco. As part of the Tri-Conference expo, which ... workflow solution, as well as its new precision medicine platform, “Crosswalk Insight: Oncology™.” ...
Breaking Medicine News(10 mins):